XLRN - Acceleron's sotatercept nabs Orphan Drug tag for PAH in Europe

The European Commission has granted Orphan Designation to Acceleron Pharma's (XLRN) sotatercept for the treatment of pulmonary arterial hypertension ((PAH)).The company is currently advancing a Phase 3 trial for sotatercept, beginning with the registrational trial known as STELLAR expected to initiate by the end of this year.Sotatercept is part of a licensing agreement with Bristol Myers Squibb, and a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR-II signaling, which is a key molecular driver of pulmonary arterial hypertension.

For further details see:

Acceleron's sotatercept nabs Orphan Drug tag for PAH in Europe